GMED · XBRL financial data

Globus Medical financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (GMED's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	384	617*	607	630	626	657*	598	745	769	826*	760	790
Cost of goods and services sold	135	265*	241	260	271	263*	195	249	253	261*	234	241
Gross profit	248	351*	365	370	—	394*	—	—	—	565*	—	—
Research and development	29	52*	57	38	35	33*	33	40	38	36*	37	36
Selling, general and administrative	156	245*	249	238	241	253*	243	304	314	318*	298	287
Total operating expenses	248	341*	357	320	—	—	—	—	—	—	—	—
Operating income (loss)	0	10*	8	50	48	60*	97	76	137	169*	150	182
Other income (expense)	2	15*	(17)	(2)	(1)	1*	1	1	2	0*	2	1
Income tax expense (benefit)	2	10*	(1)	16	5	(2)*	28	(15)	25	29*	33	38
Net income (loss)	1	15*	(7)	32	52	27*	75	203	119	141*	124	152
Earnings per share, basic USD per share	0.01	—	(0.05)	0.23	0.38	0.19*	0.55	1.50	0.88	1.05*	0.92	1.12
Earnings per share, diluted USD per share	0.01	—	(0.05)	0.23	0.38	0.19*	0.54	1.49	0.88	1.03*	0.90	1.10
Weighted average shares, basic millions of shares	114	138*	135	135	136	137*	137	135	135	134*	135	135
Weighted average shares, diluted millions of shares	115	139*	135	137	138	141*	140	136	135	137*	138	137

Balance sheet

CSV

Fiscal quarters (GMED's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	280	467	354	410	623	784	461	229	372	526	561	508
Marketable securities	189	50	80	83	72	106	—	—	19	31	69	87
Marketable securities, non-current	276	75	51	28	12	66	—	—	17	72	169	245
Accounts receivable	494	503	534	612	588	558	535	612	619	679	686	692
Inventory	905	848	816	770	718	659	664	772	772	759	773	811
Prepaid and other current assets	48	45	43	46	51	50	47	68	74	65	60	70
Total current assets	1,917	1,915	1,829	1,924	2,057	2,177	1,710	1,730	1,924	2,126	2,198	2,216
Property and equipment, net	607	587	579	572	568	562	556	588	578	564	557	534
Right-of-use asset	95	60	56	54	53	50	48	62	59	64	62	59
Goodwill	1,122	1,435	1,451	1,454	1,432	1,432	1,433	1,435	1,434	1,435	1,439	1,438
Total assets	5,356	5,086	4,944	4,994	5,086	5,252	4,711	4,961	5,096	5,303	5,440	5,488
Accounts payable	87	57	50	67	58	75	73	87	87	99	104	107
Accrued liabilities	222	240	210	216	255	261	238	282	326	334	313	301
Total current liabilities	429	392	786	794	818	856	385	425	466	498	482	479
Lease liability, non-current	100	91	90	88	86	84	82	108	105	104	100	97
Total liabilities	1,169	1,088	1,021	1,017	1,017	1,074	623	665	697	730	707	720
Retained earnings	1,348	1,137	1,047	1,074	1,126	1,153	1,036	1,214	1,292	1,388	1,512	1,527
Total stockholders' equity	4,187	3,998	3,922	3,976	4,069	4,177	4,088	4,296	4,399	4,573	4,732	4,769
Total liabilities and equity	5,356	5,086	4,944	4,994	5,086	5,252	4,711	4,961	5,096	5,303	5,440	5,488
Common shares outstanding (cover page) millions of shares	138	135	135	135	136	138	135	135	134	135	136	134

Cash flows

CSV

Fiscal quarters (GMED's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	1	15*	(7)	32	52	27*	75	203	119	141*	124	152
Stock-based compensation	23*	12*	17	13*	12*	12*	13	14*	12*	11*	13	13*
Depreciation and amortization	37*	71*	55	64*	67*	68*	66	71*	71*	69*	70	69*
Net cash from operating activities	50*	105*	52	54*	204*	210*	177	78*	250*	249*	202	210*
Purchases of property and equipment	22*	23*	29	28*	42*	17*	36	47*	36*	46*	40	33*
Net cash from investing activities	(81)*	321*	(47)	(10)*	(15)*	(104)*	131	(299)*	(76)*	(111)*	(183)	(129)*
Share repurchases	—	year only	83	1*	0*	1*	190	25*	40*	45*	0	136*
Net cash from financing activities	1*	(237)*	(116)	9*	20*	60*	(635)	(25)*	(32)*	13*	18	(134)*
Net change in cash	(27)*	188*	(113)	56*	212*	162*	(323)	(232)*	142*	154*	35	(53)*

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Globus Medical	508	790	210*	134.3M	—	Q2 FY26 10-QJun 30, 2026
MSA Safety	187	536	82*	38.5M	—	Q3 FY26 10-QSep 30, 2026
MiniMed Group	207	843	(49)	281.3M	2.3 quarters	Q1 FY27 10-QJul 31, 2026
GLAUKOS	162	211	39*	59.2M	—	Q3 FY26 10-QSep 30, 2026
Merit Medical Systems	504	416	65*	59.9M	—	Q3 FY26 10-QSep 30, 2026
iRhythm Holdings	247	224	51*	33.0M	—	Q2 FY26 10-QJun 30, 2026
Penumbra	254	410	42*	39.4M	—	Q3 FY26 10-QSep 30, 2026
TransMedics Group	491	190	17*	34.7M	—	Q2 FY26 10-QJun 30, 2026
Integer Holdings	14	450	37*	34.0M	—	Q3 FY26 10-QOct 2, 2026

Not investment advice. Not affiliated with the U.S. SEC.